How Stage 3, Stage 4, Platinum-sensitive Recurrent Uterine Serous Carcinoma Are Currently Treated, Managed

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses her presentation at the Society of Gynecologic Oncology 2022 annual meeting on the phase 2 trial of maintenance niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

Pharmacy Times interviewed Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute and associate professor at Zucker School of Medicine in Hofstra/Northwell, on her presentation at the Society of Gynecologic Oncology 2022 annual meeting on the phase 2 trial of maintenance niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

During this interview, Frimer addressed how stage 3, stage 4, and platinum-sensitive recurrent uterine serous carcinoma are currently treated and managed in the field.

Marina Frimer: So uterine serous carcinoma accounts for 40% of all endometrial cancer-related deaths, and this is a rare type but the most aggressive type of endometrial cancer.

Patients with uterine serous carcinoma share many genomic and clinical characteristics with patients that have serous ovarian cancer. So, for patients with this type of advanced stage uterine serous cancer, the current management would be platinum-based chemotherapy, plus minus radiation depending on the stage.